Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables (2016 - 2023)

Ocular Therapeutix (OCUL) has 9 years of Notes Payables data on record, last reported at $2.1 million in Q2 2023.

  • For Q2 2023, Notes Payables changed N/A year-over-year to $2.1 million; the TTM value through Jun 2023 reached $2.1 million, changed N/A, while the annual FY2020 figure was $8.3 million, N/A changed from the prior year.
  • Notes Payables reached $2.1 million in Q2 2023 per OCUL's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $8.3 million in Q4 2020 and bottomed at $2.1 million in Q1 2020.
  • Average Notes Payables over 3 years is $5.2 million, with a median of $5.2 million recorded in 2020.
  • The widest YoY moves for Notes Payables: up 299.71% in 2021, down 299.71% in 2021.
  • A 3-year view of Notes Payables shows it stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then plummeted by 74.87% to $2.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $2.1 million in Q2 2023, $8.3 million in Q1 2021, and $8.3 million in Q4 2020.